Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 1 5 30 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 1 5 30 versus PHILITH.
GILDESS 1.5/30 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet orally once daily at the same time each day.
1 mg orally once daily
None Documented
None Documented
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive